{
    "clinical_study": {
        "@rank": "72132", 
        "arm_group": {
            "arm_group_label": "ranibizumab", 
            "arm_group_type": "Experimental", 
            "description": "0.5mg of ranibizumab is injected into the vitreous cavity monthly 3 times for the 3 months then pro-re-nata (PRN) for following 3 months."
        }, 
        "brief_summary": {
            "textblock": "Exudative age-related macular degeneration (ARMD) is complicated by choroidal\n      neovascularization (CNV). Although anti-vascular endothelial growth factor treatment is the\n      gold standard treatment, recurrence is the main limitation of the treatment. The changes of\n      the CNV vascular structure is expected to provide information regarding recurrence. In the\n      eyes that the vascular structure is clearly seen in indocyanine green angiography (ICGA),\n      the vascular changes after ranibizumab injections will be investigated prospectively."
        }, 
        "brief_title": "Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "Ranibizumab is injected monthly 3 times then PRN to 6 months.\nintravitreal injection of ranibizumab: 0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.", 
                        "title": "Ranibizumab"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "31"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@lower_limit": "51", 
                                            "@upper_limit": "85", 
                                            "@value": "69"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Full Range", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "12"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "19"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "31"
                                        }
                                    }, 
                                    "sub_title": "Korea, Republic of"
                                }
                            }, 
                            "param": "Number", 
                            "title": "Region of Enrollment", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@lower_limit": "0", 
                                            "@upper_limit": "81", 
                                            "@value": "46"
                                        }
                                    }
                                }
                            }, 
                            "description": "Visual acuity was measured using a Early Treatment of Diabetic Retinopathy Study (ETDRS) chart. The ETDRS score represents the number of letters that the patient read correctly. It can be ranged from 0 to 85. An ETDRS score of 85 corresponds to 20/20 vision approximately, and a score of 35 corresponds to 20/200 vision.", 
                            "dispersion": "Full Range", 
                            "param": "Median", 
                            "title": "Median visual acuity (ETDRS)", 
                            "units": "ETDRS letter"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@lower_limit": "168", 
                                            "@upper_limit": "793", 
                                            "@value": "317"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Full Range", 
                            "param": "Median", 
                            "title": "Central subfield macular thickness (um)", 
                            "units": "micrometer"
                        }
                    ]
                }, 
                "population": "Of 39 patients completed the study, 8 patients were excluded because 6 patients had polypoidal choroidal vasculopathy, and 2 patients had poor quality of indocyanine green angiography."
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed."
            }, 
            "limitations_and_caveats": "Small number of cases, high rate of follow-up loss. Technical problem with measuring caliber of choroidal new vessels.", 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "Caliber of the largest CNV is measured using a software of IVAN (developed by Wisconsin University) that measures a caliber of retinal vessels using a semi-automatic method. An indocyanine green angiography (ICGA) image showing the vascular structures of CNV was processed to invert black and white for the analysis. The image was loaded in the software, and the course of the arteriolar CNV was indicated manually. Then average thickness of the vascular segment was calculated.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Ranibizumab is injected monthly 3 times then PRN to 6 months.\nintravitreal injection of ranibizumab: 0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.", 
                                "title": "Ranibizumab"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "24"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@lower_limit": "28.79", 
                                                    "@upper_limit": "99.40", 
                                                    "@value": "43.53"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Caliber of the largest CNV is measured using a software of IVAN (developed by Wisconsin University) that measures a caliber of retinal vessels using a semi-automatic method. An indocyanine green angiography (ICGA) image showing the vascular structures of CNV was processed to invert black and white for the analysis. The image was loaded in the software, and the course of the arteriolar CNV was indicated manually. Then average thickness of the vascular segment was calculated.", 
                                    "dispersion": "Full Range", 
                                    "param": "Mean", 
                                    "title": "Caliber of Choroidal New Vessel (CNV)", 
                                    "units": "micrometer"
                                }
                            ]
                        }, 
                        "population": "Of 31 patients included in the baseline analysis, 7 patients had the thickest vessels under  limitation of measurement.", 
                        "safety_issue": "No", 
                        "time_frame": "6 months", 
                        "title": "Caliber of Choroidal New Vessel (CNV)", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Lesion size of CNV is measured in fluorescein angiography using software, and find correlation with caliber of choroidal new vessels.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Ranibizumab is injected monthly 3 times then PRN to 6 months.\nintravitreal injection of ranibizumab: 0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.", 
                                "title": "Ranibizumab"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "31"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@lower_limit": "0.07", 
                                                    "@upper_limit": "18.09", 
                                                    "@value": "3.03"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Lesion size of CNV is measured in fluorescein angiography using software, and find correlation with caliber of choroidal new vessels.", 
                                    "dispersion": "Full Range", 
                                    "param": "Mean", 
                                    "title": "Lesion Size of CNV", 
                                    "units": "square milimeter"
                                }
                            ]
                        }, 
                        "population": "Among 39 patients who completed the study, 8 patients were excluded because of poor ICGA quality or presence of polypoidal choroidal vasculopathy.", 
                        "safety_issue": "No", 
                        "time_frame": "6 months", 
                        "title": "Lesion Size of CNV", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Visual acuity is measured using ETDRS chart, and correlation with caliber of CNV is assessed.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Ranibizumab is injected monthly 3 times then PRN to 6 months.\nintravitreal injection of ranibizumab: 0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.", 
                                "title": "Ranibizumab"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "31"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@lower_limit": "2", 
                                                    "@upper_limit": "90", 
                                                    "@value": "69"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Visual acuity is measured using ETDRS chart, and correlation with caliber of CNV is assessed.", 
                                    "dispersion": "Full Range", 
                                    "param": "Median", 
                                    "title": "Visual Acuity", 
                                    "units": "ETDRS letters"
                                }
                            ]
                        }, 
                        "population": "Among 39 patients who completed the study, 8 patients were excluded because of poor ICGA quality or presence of polypoidal choroidal vasculopathy.", 
                        "safety_issue": "No", 
                        "time_frame": "6 months", 
                        "title": "Visual Acuity", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Visual acuity is measured at baseline and 6 months using ETDRS chart. The changes was calculated by visual acuity at 6 months minus visual acuity at baseline.\nPositive values represent improvement of visual acuity, and negative values represent worsening of visual acuity at 6 months compared to baseline.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Ranibizumab is injected monthly 3 times then PRN to 6 months.\nintravitreal injection of ranibizumab: 0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.", 
                                "title": "Ranibizumab"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "31"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@lower_limit": "-36", 
                                                    "@upper_limit": "90", 
                                                    "@value": "12.5"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Visual acuity is measured at baseline and 6 months using ETDRS chart. The changes was calculated by visual acuity at 6 months minus visual acuity at baseline.\nPositive values represent improvement of visual acuity, and negative values represent worsening of visual acuity at 6 months compared to baseline.", 
                                    "dispersion": "Full Range", 
                                    "param": "Median", 
                                    "title": "Visual Acuity Changes", 
                                    "units": "ETDRS letters"
                                }
                            ]
                        }, 
                        "population": "Among 39 patients who completed the study, 8 patients were excluded because of poor ICGA quality or presence of polypoidal choroidal vasculopathy.", 
                        "safety_issue": "No", 
                        "time_frame": "6 months", 
                        "title": "Visual Acuity Changes", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "Ranibizumab is injected monthly 3 times then pro re nata (PRN) to 6 months.\nintravitreal injection of ranibizumab: 0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.", 
                        "title": "Ranibizumab"
                    }
                }, 
                "period_list": {
                    "period": {
                        "drop_withdraw_reason_list": {
                            "drop_withdraw_reason": {
                                "participants_list": {
                                    "participants": {
                                        "@count": "10", 
                                        "@group_id": "P1"
                                    }
                                }, 
                                "title": "Lost to Follow-up"
                            }
                        }, 
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "49", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "39", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "10", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }, 
                "pre_assignment_details": "This study has a single arm, and there was no assignment process.", 
                "recruitment_details": "Total 53 patients were screened and 49 patients were enrolled from Oct 2010 to Feb 2013 in Pusan National University Hospital and Inje Baik Haeundae Hospital."
            }, 
            "point_of_contact": {
                "email": "jlee@pusan.ac.kr", 
                "name_or_title": "Ji Eun Lee", 
                "organization": "Pusan National University Hospital", 
                "phone": "+82-51-240-7957"
            }, 
            "reported_events": {
                "group_list": {
                    "group": {
                        "@group_id": "E1", 
                        "description": "Ranibizumab is injected monthly 3 times then PRN to 6 months.\nintravitreal injection of ranibizumab: 0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.", 
                        "title": "Ranibizumab"
                    }
                }, 
                "serious_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "2", 
                                            "@subjects_at_risk": "49"
                                        }, 
                                        "sub_title": "Total, serious adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@events": "2", 
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "49"
                                        }, 
                                        "description": "The patient had alcholoic hepatitis, and hospitalized due to worsening of alcoholic liver cirrhosis.", 
                                        "sub_title": "Liver cirrhosis"
                                    }
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@events": "1", 
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "49"
                                        }, 
                                        "description": "As the symptom was mild and onset after more than 2 months from the last injection, the serious adverse event (SAE) was categorized as \u2018Probably not\u2019 and reported to the Institutional Review Board (IRB).", 
                                        "sub_title": "Cerebral infarction"
                                    }
                                }, 
                                "title": "Nervous system disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment"
                }
            }
        }, 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Exudative Age-related Macular Degeneration", 
        "condition_browse": {
            "mesh_term": [
                "Macular Degeneration", 
                "Neovascularization, Pathologic", 
                "Wet Macular Degeneration", 
                "Choroidal Neovascularization"
            ]
        }, 
        "detailed_description": {
            "textblock": "For patients having exudative ARMD with CNV, whose vascular structures are clearly\n      demonstrated in ICGA , ranibizumab is injected monthly three times, then pro re nata to 6\n      months. Vascular structures of CNV is investigated at baseline, 3 and 6 months using ICGA.\n      Expected number of patients are 48 eyes from 4 centers, competitively."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. age >= 50\n\n          2. Visual acuity of the study eye is between 20/400 and 20/40, and the other eye is\n             20/400 or better\n\n          3. Area of choroidal new vessel (CNV) clearly visible in indocyanine green angiography\n             (ICGA) is more then 1/2 disc area.\n\n          4. Area of CNV clearly visible in ICGA is more than half of the total CNV area.\n\n        Exclusion Criteria:\n\n          1. CNV caused by other than age-related macular degeneration. (polypoidal choroidal\n             vascularization, retinal angiomatous proliferation, degenerative myopia etc)\n\n          2. Blocked fluorescence in ICGA is more than half of the total CNV area.\n\n          3. Disciform scar\n\n          4. Previous anti-vascular endothelial growth factor (VEGF) treatment within 3 months\n\n          5. Previous any treatment of photodynamic therapy or photocoagulation\n\n          6. Previous intraocular or periocular injection of steroid within 3 months\n\n          7. Previous intraocular surgery except cataract surgery\n\n          8. Vitreo-retinal interface disease on the macula\n\n          9. Presence of other diseases may affect visual acuity (uveitis, glaucoma, diabetic\n             retinopathy, etc.)\n\n         10. Uncontrolled periocular or intraocular infection\n\n         11. History of hypersensitivity to ranibizumab treatment\n\n         12. Uncontrolled systemic diseases (hypertension, diabetes mellitus, etc.)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "49", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 11, 2013", 
        "firstreceived_results_date": "January 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01810042", 
            "org_study_id": "\uc784\uc0c120120178"
        }, 
        "intervention": {
            "arm_group_label": "ranibizumab", 
            "description": "0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.", 
            "intervention_name": "ranibizumab", 
            "intervention_type": "Drug", 
            "other_name": "intravitreal injection of ranibizumab (Lucentis, Novartis)"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "age-related macular degeneration", 
            "choroidal neovascularization", 
            "ranibizumab", 
            "indocyanine angiography"
        ], 
        "lastchanged_date": "March 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of", 
                        "zip": "602-739"
                    }, 
                    "name": "Pusan National University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of", 
                        "zip": "612-896"
                    }, 
                    "name": "Haeundae Baik Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective, Interventional Case Series, Effect of Lucentis on Indocyanine Angiographic Changes in Patients With Wet Age-related Macular Degeneration", 
        "overall_official": {
            "affiliation": "Pusan National Universtiy Hospital", 
            "last_name": "Ji Eun Lee, MH, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Caliber of the largest CNV is measured using a software of IVAN (developed by Wisconsin University) that measures a caliber of retinal vessels using a semi-automatic method. An indocyanine green angiography (ICGA) image showing the vascular structures of CNV was processed to invert black and white for the analysis. The image was loaded in the software, and the course of the arteriolar CNV was indicated manually. Then average thickness of the vascular segment was calculated.", 
            "measure": "Caliber of Choroidal New Vessel (CNV)", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "reference": [
            {
                "PMID": "15177969", 
                "citation": "Wong TY, Knudtson MD, Klein R, Klein BE, Meuer SM, Hubbard LD. Computer-assisted measurement of retinal vessel diameters in the Beaver Dam Eye Study: methodology, correlation between eyes, and effect of refractive errors. Ophthalmology. 2004 Jun;111(6):1183-90."
            }, 
            {
                "PMID": "17021318", 
                "citation": "Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1419-31."
            }, 
            {
                "PMID": "17021319", 
                "citation": "Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1432-44."
            }, 
            {
                "PMID": "16386991", 
                "citation": "Spaide RF. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol. 2006 Jan;141(1):149-56. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01810042"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Pusan National University Hospital", 
            "investigator_full_name": "Ji Eun Lee", 
            "investigator_title": "Associate professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Lesion size of CNV is measured in fluorescein angiography using software, and find correlation with caliber of choroidal new vessels.", 
                "measure": "Lesion Size of CNV", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Visual acuity is measured using ETDRS chart, and correlation with caliber of CNV is assessed.", 
                "measure": "Visual Acuity", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Visual acuity is measured at baseline and 6 months using ETDRS chart. The changes was calculated by visual acuity at 6 months minus visual acuity at baseline.\nPositive values represent improvement of visual acuity, and negative values represent worsening of visual acuity at 6 months compared to baseline.", 
                "measure": "Visual Acuity Changes", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Pusan National University Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Pusan National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2010", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}